NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SRXH
SRx Health Solutions Inc.
There isn't enough reported data to score SRXH yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SRXH Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SRXH's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SRXH PE Valuation
SRXH has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SRXH Forward outlook
There aren't enough analyst estimates for SRXH to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus SRXH down 143%.
SRXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$921.78 | +$1,209.78 |
| Q2 2024 | -$1,052.00 | +$1,412.00 |
| Q1 2024 | -$1,380.00 | +$1,181.78 |
| Q4 2023 | -$1,435.11 | +$1,185.33 |
| Q3 2023 | -$2,131.56 | +$234.66 |
| Q2 2023 | -$2,464.00 | -$293.33 |
| Q1 2023 | -$2,561.78 | -670% |
| Q4 2022 | -$2,620.44 | -$645.33 |
SRXH is still losing money, but far less than before: $921.78 per share over the past year, against $14,549.33 at its worst in early 2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the stronger quarterly revenue trend. Revenue is up 2.1% for NVO versus down 53% for SRXH.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SRXH on profitability, with a higher operating margin.
SRXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.4M | -70% |
| Q1 2026 | $3.4M | -52% |
| Q4 2025 | $2.8M | -61% |
| Q2 2025 | $11.4M | +34% |
| Q1 2025 | $7.2M | -9.4% |
| Q4 2024 | $7.2M | +26% |
| Q3 2024 | $11.4M | -13% |
| Q2 2024 | $8.5M | -19% |
SRXH's revenue has slid since its 2022 peak: $3M last quarter, down 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | +58 points |
| Q1 2026 | -53% | -38 points |
| Q4 2025 | -135% | -112 points |
| Q2 2025 | -152% | -144 points |
| Q1 2025 | -15% | +16 points |
| Q4 2024 | -23% | +200 points |
| Q3 2024 | -9.9% | +10 points |
| Q2 2024 | -8.5% | +16 points |
SRXH's operating margin was −94% last quarter, down 79 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
SRXH has the stronger cash trend. Its trailing FCF is down 12% versus its history, compared with NVO at down 14%.
SRXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$6.6M | -1858% |
| Q4 2025 | -$2.9M | -$1.7M |
| Q1 2025 | $377K | +$1.4M |
| Q4 2024 | -$1.2M | -220% |
| Q3 2024 | -$2.2M | -745% |
| Q2 2024 | $5K | -98% |
| Q1 2024 | -$1M | +$474K |
| Q4 2023 | $983K | +$3.6M |
SRXH has burned cash in most quarters: −$10M over the past year, against −$2M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SRXH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SRXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +65% | +222K shares |
| 1 year | +2706% | +542K shares |
| 3 years | +3654% | +547K shares |
SRXH has 562,284 diluted shares, up 2706% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2022 | — |
| Q4 2021 | $327,000 |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SRXH Net Leverage
SRXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SRXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.1 | Oversold |
| Stochastic | 11.2 | Oversold |
SRXH's weekly RSI is 22 (oversold) and its Stochastic is 11 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SRXH PE vs Healthcare Sector
SRXH has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has stronger trend alignment. NVO is above 1 of 5 weekly averages versus SRXH above 0 of 3.
SRXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.22 | 23% below |
| 20 week MA | $1.74 | 46% below |
| 50 week MA | $6.72 | 86% below |
SRXH is in a downtrend: it's below all three of its weekly moving averages, and 86% below its 50-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SRXH on returns for 2026, with the stronger performance.
SRXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $121.3 | $16.9 | -86% |
| 2026 YTD | $16.9 | $0.94 | -94% |
SRXH has finished every year since 2025 lower, and it's down 94% so far in 2026.